Tamoxifen in early-stage estrogen receptorpositive breast cancer: Overview of clinical use and molecular biomarkers for patient selection

OncoTargets and Therapy

Volumn 4, Issue , 2011, Pages 1-11

  Criscitiello, Carmen ^a   Fumagalli, Debora ^a   Saini, Kamal S ^a   Loi, Sherene ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Aromatase inhibitors; Endocrine therapy; Mutation; PI3K; Prediction; Resistance; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BIOLOGICAL MARKER; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FULVESTRANT; LETROZOLE; MYC PROTEIN; PROTEIN AKT1; PROTEIN PIK3CA; TAMOXIFEN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CLASSIFICATION; CANCER SURVIVAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE SEQUENCE; DRUG MECHANISM; GENE EXPRESSION; HUMAN; INTRACELLULAR SIGNALING; OVERALL SURVIVAL; PATIENT SELECTION; PROGNOSIS; REVIEW; TREATMENT PLANNING;

EID: 79953135690     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S10155     Document Type: Review

References (76)

1. Tilghman SL, Nierth-Simpson EN, Wallace R, et al. Environmental hormones: Multiple pathways for response may lead to multiple disease outcomes. Steroids. 2010;75:520-523.
2. Nicholson RI, McClelland RA, Robertson JF, et al. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer. 1999;6:373-387.
3. Pedram A, Razandi M, Levin ER. Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol. 2006;20:1996-2009.
4. Hammes SR, Levin ER. Extranuclear steroid receptors: Nature and actions. Endocr Rev. 2007;28:726-741.
5. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;365:1687-1717.
6. Osborne CK, Elledge RM, Fuqua SAW. Estrogen receptors in breast cancer therapy. Sci Med. 1996;3:32-41.
7. Arteaga CL, Osborne CK. Growth factors as mediators of estrogen/ antiestrogen action in human breast cancer cells. In: Lippman ME, Dickson RB, editors. Regulatory mechanisms in breast cancer: Advances in cellular and molecular biology of breast cancer. Boston, MA: Kluwer Academic; 1991.
8. Ellis PA, Saccani-Jotti G, Clarke R, et al. Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. Int J Cancer. 1997; 72:608-613.
9. Wiebe VJ, Osborne CK, Fuqua SAW, et al. Tamoxifen resistance in breast cancer. Crit Rev Oncol Hematol. 1993;14:173-188.
10. Horwitz KB, Jackson TA, Bain DL, et al. Nuclear receptor coactivators and corepressors. Mol Endocrinol. 1996;10:1167-1177.
11. Encarnacion CA, Ciocca DR, McGuire WL, et al. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat. 1993;26:237-246.
12. Hull DF III, Clark GM, Osborne CK, et al. Multiple estrogen receptor assays in human breast cancer. Cancer Res. 1983;43:413-416.
13. Boeddinghaus IM, Dowsett M. Comparative clinical pharmacology and pharmacokinetic interactions of aromatase inhibitors. J Steroid Biochem Mol Biol. 2001;79:85-91.
14. Buzdar A, Howell A. Advances in aromatase inhibition: Clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res. 2001;7:2620-2635.
15. Kao YC, Cam LL, Laughton CA, et al. Binding characteristics of seven inhibitors of human aromatase: A site-directed mutagenesis study. Cancer Res. 1996;56:3451-3460.
16. Johnston SR, Dowsett M. Aromatase inhibitors for breast cancer: Lessons from the laboratory. Nat Rev Cancer. 2003;3:821-831.
17. Jeng MH, Shupnik MA, Bender TP, et al. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology. 1998;139:4164-4174.
18. Santen RJ, Song RX, Zhang Z, et al. Adaptive hypersensitivity to estrogen: Mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment. J Steroid Biochem Mol Biol. 2005; 95:155-165.
19. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361:766-776.
20. Howell A, Robertson JF, Quaresma AJ, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 2002;20:3396-3403.
21. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol. 2002;20:3386-3395.
22. Howell A, Osborne CK, Morris C, et al. ICI 182,780 (Faslodex): Development of a novel, "pure" antiestrogen. Cancer. 2000;89:817-825.
23. Robertson JF, Nicholson RI, Bundred NJ, et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentyl sulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res. 2001;61:6739-6746.
24. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991;51:3867-3873.
25. Borras M, Laios I, el Khissiin A, et al. Estrogenic and antiestrogenic regulation of the half-life of covalently labeled estrogen receptor in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol. 1996;57: 203-213.
26. Dauvois S, White R, Parker MG. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci. 1993;106:1377-1388.
27. Howell A, Bergh J. Insights into the place of fulvestrant for the treatment of advanced endocrine responsive breast cancer. J Clin Oncol. 2010;28:4548-4550.
28. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081-1092.
29. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365:60-62.
30. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet. 2002;359:2131-2139.
31. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747-2757.
32. Jones SE, Seynaeve C, Hasenburg A, et al. Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. Abstr 15. 31st Annual San Antonio Breast Cancer Symposium, 2008 Dec 10-14; San Antonio, TX.
33. Rea D, Hasenburg A, Seynaeve C, et al. Five years of exemestane as initial therapy compared to 5 years of tamoxifen followed by exemestane: The TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormone-sensitive early breast cancer. Abstr 11. 32nd Annual San Antonio Breast Cancer Symposium, 2009 Dec 9-13; San Antonio, TX.
34. Bliss JM, Kilburn LS, Coleman RE, et al. Disease related outcome with long term follow-up: An updated analysis of the Intergroup Exemestane Study (IES). Abstract 12. 32nd Annual San Antonio Breast Cancer Symposium, 2009 Dec 9-13; San Antonio, TX.
35. Jonat W, Gnant M, Boccardo F, et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in post-menopausal women with hormone-sensitive early-stage breast cancer: A meta-analysis. Lancet Oncol. 2006;7:991-996.
36. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262-1271.
37. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for earlystage breast cancer. N Engl J Med. 2003;349:1793-1802.
38. Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20: 1319-1329.
39. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.
40. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci. 2001;98:10869-10874.
41. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci. 2003;100:8418-8423.
42. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci. 2003;1000:10393-10398.
43. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen treated node-negative breast cancer. N Engl J Med. 2004;351:2817-2826.
44. Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 2004;5:607-616.
45. Jansen MP, Foekens JA, van Staveren IL, et al. Molecular classification of tamoxifen resistant breast carcinomas by gene expression profiling. J Clin Oncol. 2005;23:732-740.
46. Oh DS, Troester MA, Usary J, et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol. 2006;24:1656-1664.
47. Loi S, Haibe-Kains B, Desmedt C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor positive breast carcinomas through genomic grade. J Clin Oncol. 2007;25:1239-1246.
48. Paik S, Shak S, Tang C, et al. Expression of the 21 genes in the recurrence score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer. J Clin Oncol. 2005;23(16S):510.
49. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: Understanding the molecular basis of intermediate histologic grade to improve prognosis. J Natl Cancer Inst. 2006;98:1-12.
50. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726-3734.
51. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol. 2010;11:55-65.
52. Symmans WF, Hatzis C, Sotiriou C, et al. Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol. 2010;28: 4111-4119.
53. Chanrion M, Negre V, Fontaine H, et al. A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res. 2008;14:1744-1752.
54. Miller WR, Larionov A, Renshaw L, et al. Gene expression profiles differentiating between breast cancer clinically responsive or resistant to letrozole. J Clin Oncol. 2009;27:1382-1387.
55. Mello-Grand M, Singh V, Ghimenti C, et al. Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically respectable breast cancer. Breast Cancer Res Treat. 2010;121:399-411.
56. Kok M, Linn S, Laar R. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2009;113:275-283.
57. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004;96: 926-935.
58. Osborne CK, Bardou V, Hopp TA, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003;95:353-361.
59. Ellis MJ, Tao Y, Young O, et al. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol. 2006;24:3019-3025.
60. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008;68:6084-6091.
61. Loi S, Haibe-Kains B, Majjaj S, et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A. 2010;107:10208-10213.
62. di Cosimo S, Baselga J. Phosphoinositide 3-kinase mutations in breast cancer: A "good" activating mutation? Clin Cancer Res. 2009;15: 5017-5019.
63. Kalinsky K, Jacks LM, Heguy A. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res. 2009;15: 5049-5059.
64. Ellis MJ, Lin L, Crowder R. Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2010;119:379-390.
65. Salvesen HB, Carter SL, Mannelqvist M. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci U S A. 2009;106: 4834-4839.
66. Carpten JD, Faber AL, Horn C. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature. 2007;448: 439-444.
67. Courjal F, Cuny M, Simony-Lafontaine J, et al. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: Definition of phenotypic groups. Cancer Res. 1997;57:4360-4367.
68. Theillet C, Adelaide J, Louason G, et al. FGFRI and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers. Genes Chromosomes Cancer. 1993;7:219-226.
69. Elbauomy Elsheikh S, Green AR, Lambros MB. FGFR1 amplification in breast carcinomas: A chromogenic in situ hybridisation analysis. Breast Cancer Res. 2007;9:R23.
70. Turner N, Pearson A, Sharpe R, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010;70:2085-2094.
71. Musgrove EA, Sergio CM, Loi S, et al. Identification of functional networks of estrogen-and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer. PloS One. 2008;3: e2987.
72. Butt AJ, McNeil CM, Musgrove EA, et al. Downstream targets of growth factor and oestrogen signalling and endocrine resistance: The potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer. 2005;12 Suppl 1:S47-S59.
73. Cheang M, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736-750.
74. Burstein HJ, Prestrud AA, Seidenfeld J. American Society of Clinical Oncology clinical practice guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010;28:3784-3796.
75. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: Breast cancer. Available at: http://www.nccn.org/ professionals/physician_gls/PDF/breast.pdf. Accessed 2010 May 25.
76. Viale G, Regan MM, Dell'Orto P, et al. Central review of ER, PgR and HER2 in BIG 1-98 evaluating letrozole vs letrozole followed by tamoxifen vs tamoxifen followed by letrozole as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive breast cancer. Abstract 76. 32nd Annual San Antonio Breast Cancer Symposium, 2009 Dec 9-13; San Antonio, TX.